A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy

Pilot Study for Evaluating the Efficacy and Tolerability of Induction Therapy With Recombinant Human Erythropoietin Beta (rHuEPO) NeoRecormon® - at High Dose in Anemic Cancer Patients Treated With Chemotherapy

This study will evaluate the efficacy and tolerability of subcutaneous (SC) or intramuscular (IM) recombinant human erythropoietin beta (r-HuEPO) in participants with anemia and histologically or cytologically confirmed cancer.

Inclusion Criteria:

• Histological or cytological confirmed cancer
• Participants who are treated with at least first line chemotherapy
• Hemoglobin less than (<) 11 grams per deciliter (g/dL)
• Participants able to receive iron supplement, if necessary

Exclusion Criteria:

• History of hypersensitivity to active or inactive excipients of r-HuEPO
• Insufficient controllable hypertension
• Thalassemic syndromes
• Anemia caused by hematic loss
• Women who are pregnant or lactating